Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥1,497 JPY
Change Today -13.00 / -0.86%
Volume 89.8K
4573 On Other Exchanges
Symbol
Exchange
Tokyo
As of 2:00 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

r-tech ueno ltd (4573) Snapshot

Open
¥1,494
Previous Close
¥1,510
Day High
¥1,516
Day Low
¥1,485
52 Week High
03/9/15 - ¥2,324
52 Week Low
04/8/15 - ¥1,178
Market Cap
28.9B
Average Volume 10 Days
215.9K
EPS TTM
¥71.37
Shares Outstanding
19.3M
EX-Date
03/29/16
P/E TM
21.0x
Dividend
¥35.00
Dividend Yield
2.00%
Current Stock Chart for R-TECH UENO LTD (4573)

Related News

No related news articles were found.

r-tech ueno ltd (4573) Related Businessweek News

No Related Businessweek News Found

r-tech ueno ltd (4573) Details

R-Tech Ueno, Ltd. engages in the research, development, manufacture, marketing, and sale of pharmaceutical products for the treatment of ophthalmology and dermatology worldwide. The company offers Rescula eye drops to treat glaucoma and ocular hypertension. Its product pipeline comprises UF-021, which is in Phase IIb clinical trials to treat retinitis pigmentosa; RU-101 which is in Phase IIa clinical trials for the treatment of dry eye; and RK-023 that is in Phase IIa clinical trials to treat alopecia. The company is also developing RTU-1096 for the treatment of diabetes macular edema and diabetic neuropathy; and RTU-009 for treating acute cerebral infarction and graft-versus-host diseases. In addition, it engages in contract manufacturing of injections, eye drops, liquid drugs, liquid-filled hard capsules, solid formulations, and ointments. R-Tech Ueno, Ltd. was founded in 1989 and is headquartered in Tokyo, Japan.

80 Employees
Last Reported Date: 06/24/15
Founded in 1989

r-tech ueno ltd (4573) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

r-tech ueno ltd (4573) Key Developments

R-Tech Ueno, Ltd. to Conduct Collaborative Research with Autonomous University of Barcelona and Vall d’Hebron Institute of Research

R-Tech Ueno, Ltd. has announced plans to conduct collaborative research with Autonomous University of Barcelona (UAB) and Vall d’Hebron Institute of Research (VHIR), in Catalonia (Spain) to develop a novel VAP-1 inhibitor (Development code: RTU-009) for treatment of cerebral infarction. RTU-009 is a novel VAP-1 inhibitor, having an anti-inflammatory and neuroprotective effect. It is confirmed that RTU-009 has a neuroprotective effect similar to Edaravone (Radicut), the brain protective agent, and a cerebral dysfunction improving effect when applied in combination with t-PA treatment in animal stroke models. It is currently undergoing non-clinical studies to proceed to Phase I clinical trials. Though an oral VAP-1 inhibitor named RTU-1096 is under development, RTU-009 is the novel VAP-1 inhibitor that has been developed as an injection agent targeting for treatment of acute cerebral infarction. To explore the possibility of the clinical application of RTU-009 for treating cerebral infarction as a POC (Proof of Concept) trials (Early Phase II clinical trials), the company started collaborative research using stroke animal models with the group led by Professor Unzeta of the Institute of Neuroscience, UAB, and the group led by Dr. Montaner, MD, of the Neurovascular Research Laboratory of Vall d’Hebron Institute of Research, the research centre of the UAB-affiliated Vall d'Hebron University Hospital, who are active in the front line of clinical as well as research activity.

R-Tech Ueno, Ltd. to Conduct Collaborative Research with Department of Ophthalmology

R-Tech Ueno, Ltd. has announced plans to conduct collaborative research with a group led by Professor Susumu Ishida and Associate Professor Kousuke Noda of the Department of Ophthalmology. The research is in the application of a new VAP-1 inhibitor (Development Code: RTU-1096), which is under the development for treatment of diabetic retinopathy (DR) and diabetic macular edema. RTU-1096 is a VAP-1 inhibitor, having an anti-inflammatory and immunomodulatory effect that is currently undergoing a Phase I clinical trial in Japan. This collaborative research is to conduct an examination at Hokkaido University to verify the therapeutic effect of RTU-1096 on diabetes ophthalmic complications, such as DR and diabetic macular edema. This examination serves to explore the possibility of the clinical application of the VAP-1 inhibitor for treating DR and diabetic macular edema, in preparation for the POC (Proof of Concept) trials in the future, otherwise known as the Early Phase II clinical trials. Going forward, the company will further accelerate development of the VAP-1 inhibitor as an innovative treatment, setting diabetic complications of DR and diabetic macular edema as the top priority target disease.

R-Tech Ueno, Ltd. Reports Non Consolidated Earnings Results for the Year Ended March 31, 2015; Provides Earnings Outlook for the First Half and Full Year of Fiscal 2016; Announces Year End Dividend, Payable on June 24, 2015; Provides Dividend Outlook for the Fiscal Year Ending March 31, 2016

R-Tech Ueno, Ltd. reported non consolidated earnings results for the year ended March 31, 2015. For the period, the company’s net sales were ¥6,681 million against ¥5,618 million a year ago. Operating income was ¥1,731 million against ¥1,419 million a year ago. Ordinary income was ¥1,884 million against ¥1,477 million a year ago. Net income was ¥1,377 million against ¥1,062 million a year ago. Diluted net income per share was ¥70.87 against ¥54.68 a year ago. Return on equity was 13.0% against 12.3% a year ago. Cash flows from operating activities were ¥1,138 million against ¥1,428 million a year ago. For the fiscal year ended March 31, 2015, the company announced year end dividend of ¥30.00 per share payable on June 24, 2015. For the fiscal year ending March 31, 2016, the company expects year end dividend of ¥35.00 per share. For the first half of fiscal year 2016, the company expects net sales of ¥3,384 million, operating income of ¥594 million, ordinary income of ¥596 million and net income of ¥417 million or ¥21.61 per share. For the fiscal year ending March 31, 2016, the company expects net sales of ¥7,483 million, operating income of ¥2,300 million, ordinary income of ¥2,303 million and net income of ¥1,612 million or ¥83.48 per share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4573:JP ¥1,497.00 JPY -13.00

4573 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4573.
View Industry Companies
 

Industry Analysis

4573

Industry Average

Valuation 4573 Industry Range
Price/Earnings 21.1x
Price/Sales 4.3x
Price/Book 2.4x
Price/Cash Flow 20.8x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact R-TECH UENO LTD, please visit www.rtechueno.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.